Self-amplifying RNA and vaccine innovation: getting from concept to clinic
Biomanufacturers using self-amplifying RNA, or saRNA, could enjoy significant advantages; the technology can offer both greater disease-neutralising antibodies and faster production timelines. But its novelty means caution is needed when translating theory into practice
